Brenda Wu
Neurology · New Brunswick, NJNPI 1255406443
Payments from drug & device makers
Across 740 payments — averaging $22.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Catalyst Pharmaceuticals, Inc.$6K
- UCB, Inc.$2K
- Eisai Inc.$1K
- AbbVie$1K
- Supernus Pharmaceuticals, Inc.$791
- Neurelis, Inc.$716
- plus $5K from 31 others
What the payments were for
- Speaking & faculty fees$4,00024%
- Travel & lodging$1,1377%
- Food & beverage$11,39169%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Catalyst Pharmaceuticals, Inc. | 15 | $5,659 |
| UCB, Inc. | 128 | $1,809 |
| Eisai Inc. | 102 | $1,452 |
| AbbVie(2 entities) | 76 | $1,091 |
| Supernus Pharmaceuticals, Inc. | 70 | $791 |
| Neurelis, Inc. | 50 | $716 |
| SK Life Science, Inc. | 42 | $609 |
| Lilly USA, LLC | 29 | $533 |
| Amgen | 16 | $431 |
| Aquestive Therapeutics, Inc. | 32 | $387 |
| Sunovion Pharmaceuticals Inc. | 20 | $336 |
| Boehringer Ingelheim | 2 | $250 |
| Vanda Pharmaceuticals Inc. | 19 | $247 |
| Pfizer | 16 | $244 |
| Lundbeck LLC | 19 | $232 |
| Sumitomo Pharma America, Inc. | 15 | $220 |
| Otter Pharmaceuticals, LLC | 15 | $187 |
| Biogen | 10 | $144 |
| Livanova USA, Inc. | 7 | $127 |
| Biohaven Pharmaceuticals, Inc. | 7 | $121 |
| Novo Nordisk | 1 | $117 |
| Intra-sana Laboratories | 1 | $111 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $110 |
| Novartis | 7 | $102 |
| AstraZeneca | 1 | $96 |
| Aucta Pharmaceuticals, Inc. | 9 | $92 |
| Aprecia Pharmaceuticals, LLC | 6 | $75 |
| Jazz Pharmaceuticals Inc. | 4 | $64 |
| Life Molecular Imaging Ltd | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Merck | 2 | $27 |
| C2n Diagnostics, LLC | 1 | $22 |
| Immedica Pharma US, Inc. | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Greenwich Biosciences, Inc. | 1 | $15 |
| OWP Pharmaceuticals, Inc. | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,550 in reported general payments places this provider in the 75th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FinteplaFenfluramine Hcl | 58 | $905,853 |
| SympazanClobazam | 137 | $246,581 |
| FycompaPerampanel | 149 | $188,807 |
| Trokendi XrTopiramate | 74 | $124,916 |
| Topiramate ErTopiramate | 155 | $102,201 |
| AptiomEslicarbazepine Acetate | 55 | $99,200 |
| XcopriCenobamate | 63 | $96,135 |
| BriviactBrivaracetam | 69 | $88,741 |
| OnfiClobazam | 16 | $66,925 |
| Oxtellar XrOxcarbazepine | 47 | $59,382 |
| NayzilamMidazolam | 19 | $36,183 |
| Aimovig AutoinjectorErenumab-Aooe | 21 | $15,835 |
| Oxcarbazepine | 127 | $6,922 |
| DayvigoLemborexant | 22 | $6,911 |
| Clobazam | 64 | $5,219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Briviact, Nayzilam | $1,809 | $1,030,777146 claims |
| Aquestive Therapeutics, Inc.Sympazan | $387 | $246,581137 claims |
| Eisai Inc.Fycompa, Dayvigo | $1,452 | $195,717171 claims |
| Supernus Pharmaceuticals, Inc.Trokendi Xr, Oxtellar Xr | $791 | $184,298121 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $336 | $99,20055 claims |
| SK Life Science, Inc.Xcopri | $609 | $96,13563 claims |
| Lundbeck LLCOnfi | $232 | $66,92516 claims |
| Upsher-smith Laboratories LLCTopiramate | $15 | $1,322137 claims |
| Lilly USA, LLCOlanzapine | $533 | $33514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 521 neurology providers in New Jersey.
Other neurology in New Brunswick
- Lawrence GolbeNew Brunswick$449K
- Gian PalNew Brunswick$266K
- Suhayl Dhib-JalbutNew Brunswick$258K
- Shan ChenNew Brunswick$189K
- Daniel SchneiderNew Brunswick$137K
- Mary Ann PiconeTeaneck$2.8M
- Steven BromleyAudubon$1.7M
- David DuncanNeptune$1.5M
- Lana Zhovtis RyersonNeptune$1.3M
- Amos KatzEatontown$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.